Harrow Health Revenue and Competitors

Imprimis Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing proprietary compounded drug therapies to physicians and patients in the United States. The company owns, markets, and sells a portfolio of proprietary combination formulations in ophthalmology and urology. Its ophthalmic formulations include anti-inflammatory and anti-bacterial combination formulations, such as Tri-Moxi, a compounded formulation that is a combination of triamcinolone acetonide and moxifloxacin hydrochloride used as an injection during ocular surgery, as well as an eye drop in pre-and post-ocular surgery; and Tri-Moxi-Vanc, a compounded formulation, which is a combination of triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin used as an injection during ocular surgery. The company?s ophthalmic formulations also comprise Pred-Moxi, a compounded formulation that is a combination of prednisolone and moxifloxacin hydrochloride used as an eye drop in pre-and post-ocular surgery. Imprimis Pharmaceuticals, Inc. markets its ophthalmic formulations under the Dropless Therapy and LessDrops brands. It also offers urology formulations, including heparin and alkalinized lidocaine, a patented urologic formulation, which is delivered directly to the bladder for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of certain fibrotic conditions, including Peyronie?s disease. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

keywords:Sales and Marketing